← All trials
NCT05421663
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2022
- Primary completion
- May 31, 2025
- Completion date
- Jul 31, 2038
- First posted
- Jun 16, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cellular Biomedicine Group Ltd.Lead sponsor
- City of Hope National Medical CenterCollaborator
- City of Hope National Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.